124323-77-9

Upstream product

• 122670-62-6 2-Bromo-5-(trifluoromethyl)-6-methoxy-1-naphthalene-carboxylic acid 
• 108-95-2 phenol 
• 85674-78-8 5-Methyl-2-methoxy-1-(trifluoromethyl)naphthalene 
• 122670-67-1 2-bromo-6-methoxy-1-methyl-5-(trifluoromethyl)naphthalene 
• 122670-66-0 2-Bromo-1-(bromomethyl)-5-(trifluoromethyl)-6-methoxynaphthalene 
• 122670-61-5 2-Bromo-5-(trifluoromethyl)-6-methoxy-1-naphthalene-methanol 

Downstream Products

• 124323-81-5 [(6-Methoxy-2-phenoxy-5-trifluoromethyl-naphthalene-1-carbothioyl)-methyl-amino]-acetic acid methyl ester 
• 124323-78-0 [(6-Methoxy-2-phenoxy-5-trifluoromethyl-naphthalene-1-carbonyl)-methyl-amino]-acetic acid methyl ester 
• 134057-51-5 N-[[6-methoxy-2-phenoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine 
• 124323-62-2 N-[[6-methoxy-2-phenoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-N-methylglycine 

Relevant academic research and scientific papers

Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives

A series of aldose reductase inhibitors were prepared which were analogues of the potent, orally active inhibitor tolrestat (1). These compounds (5, 7, 9, and 10) have an extra substituent on one of the unoccupied positions on the naphthalene ring of 1. P

N-NAPHTHOYLGLYCINES AS ALDOSE REDUCTASE INHIBITORS

Disclosed herein are N-naphthoylglycines and methods of their preparation. The N-naphthoylglycines are novel aldose reductase inhibitors useful for the treatment or prevention of diabetic complications